论文部分内容阅读
目的对比美沙拉嗪联合双歧三联活菌胶囊治疗溃疡性结肠炎(UC)的疗效及其对其调节性T细胞与炎性因子的影响。方法随机抽取2015年6月—2016年8月郑州大学附属南阳中心医院收治的84例UC患者,通过随机数表法分组,各42例。对照组采用美沙拉嗪,研究组采用美沙拉嗪+双歧三联活菌胶囊,两组均持续治疗1个月。统计两组临床疗效、不良反应发生率,分析治疗前后血清炎性细胞因子指标[白细胞介素-8(IL-8)、IL-10、肿瘤坏死因子-α(TNF-α)]水平、CD4+CD25+调节性T细胞占CD4+T细胞百分比变化情况。结果研究组总有效率(88.10%)高于对照组(69.05%),差异有统计学意义(P<0.05);治疗前两组IL-8、IL-10、TNF-α、CD4+CD25+调节性T细胞占CD4+T细胞百分比对比差异无统计学意义(P>0.05),治疗后两组各指标水平较治疗前改善,且研究组IL-8、TNF-α水平低于对照组,IL-10、CD4+CD25+调节性T细胞占CD4+T细胞百分比高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率(9.52%)与对照组(7.14%)对比,差异无统计学意义(P>0.05)。结论联合采用美沙拉嗪及双歧三联活菌胶囊治疗溃疡性结肠炎效果显著,可改善炎性因子及调节性T细胞水平,提高治疗效果,安全性较高。
Objective To compare the curative effect of mesalamine and bifid triple viable capsule on ulcerative colitis (UC) and its effect on its regulatory T cells and inflammatory cytokines. Methods A total of 84 patients with UC who were admitted to Nanyang Central Hospital Affiliated to Zhengzhou University from June 2015 to August 2016 were randomly selected and divided into two groups according to random number table. In the control group, mesalazine was used. In the study group, mesalazine + bifidobacterium triple viable capsule was used, and both groups were treated for one month. The clinical efficacy and incidence of adverse reactions in the two groups were statistically analyzed. The levels of serum inflammatory cytokines (interleukin-8, IL-10, TNF-α) and CD4 + CD25 + regulatory T cells accounted for the percentage of CD4 + T cells. Results The total effective rate (88.10%) in the study group was significantly higher than that in the control group (69.05%) (P <0.05). The levels of IL-8, IL-10, TNF-α and CD4 + CD25 + There was no significant difference in the percentage of T cells among CD4 + T cells (P> 0.05). After treatment, the levels of IL-8 and TNF-α in the study group were lower than those in the control group -10, the percentage of CD4 + CD25 + regulatory T cells in CD4 + T cells was significantly higher than that in control group (P <0.05). The incidence of adverse reactions in study group (9.52%) was significantly higher than that in control group (7.14%) , The difference was not statistically significant (P> 0.05). Conclusion The combination of Mesalazine and Bifid triple viable capsule in the treatment of ulcerative colitis is effective and can improve the level of inflammatory cytokines and regulatory T cells and improve the therapeutic effect and safety.